|Bid||18.14 x 3200|
|Ask||18.15 x 800|
|Day's Range||17.74 - 18.30|
|52 Week Range||15.50 - 21.95|
|Beta (3Y Monthly)||1.03|
|PE Ratio (TTM)||22.37|
|Forward Dividend & Yield||0.79 (3.88%)|
|1y Target Est||27.97|
Japanese Olympic Committee (JOC) chief Tsunekazu Takeda, who is under investigation in France for suspected corruption and will step down from his role in June, is no longer an International Olympic Committee member, the IOC said on Tuesday.
Amid charges of corruption by French prosecutors, Japan's Olympic Committee president will step down at the end of his term in June. Justin Solomon reports.
Investment company Velanne Asset Management Ltd buys Takeda Pharmaceutical Co, sells Fox Corp during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Velanne Asset ...
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Takeda Pharmaceutical Company Limited (TAK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.
SAO PAULO/FRANKFURT, April 4 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said. The investment banking unit of Bank of America Corp is managing the sale and has invited Brazilian pharmaceutical companies Ache Laboratorios Farmaceuticos SA, EMS Pharma, Biolab Farmaceutica SA and Eurofarma Laboratorios SA to bid for the local unit, the sources added, asking for anonymity in discussing private talks. Financial investors such as private equity firm Advent International Corp have also been invited to participate, one of the sources added.
OSAKA, Japan-- -- Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab Vedolizumab set to be the only maintenance therapy to offer the option of intravenous or subcutaneous formulations across ulcerative colitis and Crohn’s disease Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency has accepted a ...
OSAKA, Japan-- -- Impact on patient quality of life quantified including long-term renal and cardiovascular complications Final outcomes of 6 year study into continuous use of rhPTH shows improvements in key measurements of mineral homeostasis Takeda Pharmaceutical Company Limited this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential ...
Takeda Pharmaceutical Company Limited (TAK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
A pair of plasma donation centers is headed to the Orlando area with dozens of new jobs. Bannockburn, Illinois-based BioLife Plasma Services LP, a subsidiary of Japanese drug company Takeda Pharmaceutical Co. Ltd., will open its first Orlando location March 23 at 867 Good Homes Road in Orlando. "As the demand for plasma-derived therapies increases, BioLife is expanding throughout the United States to help meet that demand," Melissa Richter, a U.S. field marketing representative for BioLife Plasma Services, told Orlando Business Journal.
Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program
CAMBRIDGE, Mass.-- -- FLEXBUMIN 25% , USP, 25% Solution is indicated for hypovolemia, hypoalbuminemia, , and nephrosis), cardiopulmonary bypass surgery, and hemolytic disease of the newborn . Albumin is not indicated as an intravenous nutrient Takeda received its first FDA approval for the Georgia facility, to manufacture GAMMAGARD LIQUID® 10% Solution, in June ...
Vedolizumab superior to adalimumab in achieving clinical remission and mucosal healing at week 52 in patients with moderately to severely active ulcerative colitis
DALLAS, March 8, 2019 /PRNewswire/ -- National law firm Fears Nachawati is launching an immediate investigation into the popular gout drug Uloric, manufactured by Takeda Pharmaceuticals (TAK), after the U.S. Food and Drug Administration (FDA) issued a boxed warning stemming from the increased risk of death from Uloric use. On Feb. 21, 2019, the FDA concluded that there is an increased risk of death from Uloric (febuxostat) compared to another gout medicine, Zyloprim (allopurinol.) This conclusion is based on the FDA's in-depth review of results from a clinical safety study, which found a higher risk of heart-related deaths when taking Uloric.
OTTAWA , Feb. 28, 2019 /CNW Telbec/ - As part of International Rare Disease Day activities across the country and in collaboration with ten patient associations, Takeda Canada Inc. is privileged to launch a new social media campaign to educate Canadians about the importance of access to early diagnosis, treatment and resources by sharing the compelling stories of patients living with rare diseases. Lori's story began when she was 5 years old.
An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market. The 3rd U.S. Circuit Court of Appeals ruled that a federal court in Delaware had been correct in dismissing the FTC's lawsuit against Shire. Shire was acquired by Takeda Pharmaceutical Co last month.
Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey Rare diseases remain undiagnosed as patients ...